resolving all patent litigation related to Axsome’s AUVELITY® (dextromethorphan HBr – bupropion HCl) product. The litigation resulted from submission by Teva of an Abbreviated New Drug ...
Promethazine HCl 6.25mg, dextromethorphan HBr 15mg; per 5mL; liq; contains alcohol 7%. Dextromethorphan is an antitussive agent and, unlike the isomeric levorphanol, it has no analgesic or ...
The settlement resolves all patent litigation related to Axsome’s Auvelity (dextromethorphan HBr – bupropion HCl ... Teva submitting an Abbreviated New Drug Application to the U.S. Food ...
Background: Dextromethorphan (DM), the d-isomer of ... extrapolated to suggest that pregnant women should not use this drug because of the risk of birth defects. We conducted a controlled study ...
Zacks Investment Research on MSN23d
Axsome (AXSM) Surges 20.2%: Is This an Indication of Further Gains?Axsome Therapeutics (AXSM) shares soared 20.2% in the last trading session to close at $127.08. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...
resolving all patent litigation related to Axsome’s AUVELITY® (dextromethorphan HBr – bupropion HCl) product. The litigation resulted from submission by Teva of an Abbreviated New Drug ...
Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback